Medical News: ADA: Good Efficacy, Safety With Linagliptin - in Meeting Coverage, ADA from MedPage Today
Links shared publicly online about this topic.
- 185total visits
Medical News: ADA: Good Efficacy, Safety With Linagliptin - in Meeting Coverage, ADA from MedPage Today
SAN DIEGO -- The recently approved DPP-4 inhibitor linagliptin (Tradjenta) provided comparable control in type 2 diabetes to glimepiride (Amaryl) when added to metformin and cut the risk of cardiovasc
View full resource at medpagetoday.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Amaryl, News, Safety, Medical
Most Recently Shared on June 28, 2011 at 6:06 pm By:
ADA: Good Efficacy, Safety With Linagliptin (CME/CE) http://bit.ly/jTsrWK
Advertisement
